Cardiac glycosides display selective efficacy for STK11 mutant lung cancer
暂无分享,去创建一个
Gordon B. Mills | Ningning He | Mee Song | Somin Kim | Woo-Young Kim | Sukjoon Yoon | Nayoung Kim | Sang-Min Jeon | G. Mills | Nayoung Kim | Yong-Yeon Cho | Sukjoon Yoon | Woo-Young Kim | Cheol-Jung Lee | H. Lee | Sang-Min Jeon | Hwa Young Yim | Ju ng-Hyun Kim | Somin Kim | Yong-Yeon Cho | Hye Suk Lee | Cheol-Jung Lee | Ju Hyun Kim | Jin-Sung Choi | Euna Jeong | Mee Song | Ningning He | Jin-Sung Choi | E. Jeong | Yong‐Yeon Cho
[2] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[3] Y. Hasin,et al. Sodium Pump Inhibition, Enhanced Calcium Influx via Sodium‐Calcium Exchange, and Positive Inotropic Response in Cultured Heart Cells , 1985, Circulation research.
[4] Xuejun Jiang,et al. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. , 2012, The international journal of biochemistry & cell biology.
[5] K. Winnicka,et al. Apoptosis-mediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells , 2007, Archives of pharmacal research.
[6] R. Kiss,et al. Cardiotonic steroids on the road to anti-cancer therapy. , 2007, Biochimica et biophysica acta.
[7] Laura La Paglia,et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. , 2010, Cancer treatment reviews.
[8] G. Mills,et al. Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D , 2014, Molecular Cancer Therapeutics.
[9] M. Zou,et al. AMPK in cardiovascular health and disease , 2010, Acta Pharmacologica Sinica.
[10] O. Fedorova,et al. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different alpha-subunit isoforms. , 1997, American journal of hypertension.
[11] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[12] M. Suraokar,et al. Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase α subunits as drug targets , 2008, Molecular Cancer Therapeutics.
[13] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[14] O. Fedorova,et al. Inhibition of Na/K ATPase From Rat Aorta by Two Na/K Pump Inhibitors, Ouabain and Marinobufagenin: Evidence of Interaction With Different α-Subunit Isoforms , 1997 .
[15] L. Zitvogel,et al. Anticancer activity of cardiac glycosides , 2012, Oncoimmunology.
[16] Robert N. Stavins,et al. ENVIRONMENTAL REGULATION IN THE 1990 S : A RETROSPECTIVE ANALYSIS , 2003 .
[17] T. Snow. Drugs for atrial fibrillation , 1996, BMJ.
[18] Eleftherios P. Diamandis,et al. Novel therapeutic applications of cardiac glycosides , 2008, Nature Reviews Drug Discovery.
[19] Ellen T. Gelfand,et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.
[20] J. de Castro Carpeno,et al. KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach. , 2013, Translational lung cancer research.
[21] G. Semenza,et al. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.
[22] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[23] D. Neil Hayes,et al. LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.
[24] Liu Wei,et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.
[25] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[26] K. Wasmer,et al. Effects of Digoxin on Acute, Atrial Fibrillation–Induced Changes in Atrial Refractoriness , 2000, Circulation.
[27] Mee Song,et al. Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer , 2015, International journal of oncology.
[28] S. Soltoff,et al. Regulation of ERK1/2 by ouabain and Na-K-ATPase-dependent energy utilization and AMPK activation in parotid acinar cells. , 2008, American journal of physiology. Cell physiology.
[29] Elizabeta Bab-Dinitz,et al. Selectivity of Digitalis Glycosides for Isoforms of Human Na,K-ATPase* , 2010, The Journal of Biological Chemistry.
[30] F. Takatsu,et al. Effect of Aging on the Incidence of Digoxin Toxicity , 2000, The Annals of pharmacotherapy.
[31] H. Clevers,et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer , 2007, Oncogene.
[32] A. Tsimberidou,et al. Common cardiovascular medications in cancer therapeutics. , 2011, Pharmacology & therapeutics.
[33] Jun O. Liu,et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.
[34] C. Walker,et al. The role of LKB1 and AMPK in cellular responses to stress and damage , 2011, FEBS letters.
[35] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[36] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[37] Yiling Lu,et al. Systematic analysis of genotype‐specific drug responses in cancer , 2012, International journal of cancer.
[38] Sukjoon Yoon,et al. MACE: mutation-oriented profiling of chemical response and gene expression in cancers , 2015, Bioinform..
[39] A. Hollman. Digoxin comes from Digitalis lanata , 1996, BMJ.
[40] K. Kohn,et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.
[41] K. Kohn,et al. 268 CellMiner: a Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set , 2012 .